Peter L Salk, MD

Peter Salk has served as president of the Jonas Salk Legacy Foundation in La Jolla since 2009 and as a visiting professor (2015-18) and part-time professor (2018-present) in Pitt's Department of Infectious Diseases and Microbiology.

He graduated from Harvard University in 1965 and from Johns Hopkins University School of Medicine in 1969, and undertook two years of house staff training in internal medicine at the University Hospitals of Cleveland. He then worked in his father’s laboratory at the Salk Institute for Biological Studies from 1972-1984 conducting research on the biology and immunotherapy of cancer and autoimmune disease and strategies for vaccine production. He worked again with his father from 1991-1995 on a project to develop an inactivated vaccine for HIV infection, and subsequently engaged in the introduction of AIDS treatment programs in Africa and Asia.

His current activities include educating the public regarding his father’s life and work and exploring approaches to reducing the severity of various public health problems and to improving prospects for smoothing the transition to a sustainable human future.

1965 | Harvard University

1969 | Johns Hopkins University School of Medicine

Salk, J. and Salk, P.L.  Immunologic medicine:  a perspective.  Behring Inst. Mitt. 63, 211‑213, 1979.

 

Pearlstein, E., Salk, P.L., Yogeeswaran, G. and Karpatkin, S.  Correlation between spontaneous metastatic potential, platelet-aggregating activity of cell surface extracts, and cell surface sialylation in 10 metastatic-variant derivatives of a rat renal sarcoma cell line.  Proc. Natl. Acad. Sci. USA 77, 4336-4339, 1980.

 

Yogeeswaran, G. and Salk, P.L.   Metastatic potential is positively correlated with cell surface sialylation of cultured murine tumor cell lines.  Science 212, 1514-1516, 1981.

 

Petricciani, J.C., Salk, P.L., Salk, J. and Noguchi, P.D.  Theoretical considerations and practical concerns regarding the use of continuous cell lines in the production of biologics.  Develop. biol. Standard. 50, 15-25, 1982.

 

van Wezel, A.L., van der Marel, P., Van Beveren, C.A., Verma, I., Salk, P. and Salk, J.  Detection and elimination of cellular nucleic acids in biologicals produced on continuous cell lines.  Develop. biol. Standard. 50, 59-69, 1982.

 

Salk, J. and Salk, P.L.  An evolutionary approach to world problems.  Fourth Extraordinary Session of the General Conference, United Nations Educational, Scientific and Cultural Organization.  Conference Documents.  (UNESCO, Paris, 1982), 12 pp.

 

Böhlen, P., Esch, F., Wegemer, D., Salk, P. and Dennert, G.  Isolation and partial characterization of human T-cell growth factor.  Biochem. Biophys. Res. Commun. 117, 623‑630, 1983.

 

Salk, P.L.  An evolutionary approach to world peace.  Modern Science and Vedic Science 5, 184-198, 1992.

 

Atlan, H., Gersten, M., Salk, P.L. and Salk, J.  Can AIDS be prevented by T-cell vaccination?  Immunol. Today 14, 200-202, 1993.

 

Salk, J., Bretscher, P.A., Salk, P.L., Clerici, M. and Shearer, G.M.  A strategy for prophylactic vaccination against HIV.  Science 260, 1270-1272, 1993.

 

Salk, J., Bretscher, P.A., Salk, P.L., Clerici, M. and Shearer, G.M.  Protection from HIV Infection or AIDS?  Science 262, 1075-1076, 1993.

 

Vaslin, B., Le Grand, R., Vogt, G., Benveniste, O., Gras, G., Roques, P., Stoeckel, P., Salk, P. L., Salk, J. and Dormont, D.  Induction of humoral and cellular immunity to simian immunodeficiency virus:  what are the requirements for protection?  Vaccine 12, 1132-1140, 1994.

 

Salk, P.L. and Salk, J.  Cell-mediated immunologic memory in prevention and treatment of HIV disease.  Res. Immunol. 145, 629-635, 1994.

 

Salk, P.L. and Salk, J.  Overview of cytokine climate, CD8+T cells and therapies in AIDS.  Res. Immunol. 145, 717-720, 1994.

 

Levine, A.M., Groshen, S., Allen, J., Munson, K.M., Carlo, D.J., Daigle, A.E., Ferre, F., Jensen, F.C., Richieri, S.P., Trauger, R.J., Parker, J.W., Salk, P.L., and Salk, J.  Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 immunogen:  long-term follow-up.  J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 11, 351-364, 1996.

 

Lanza, P., Moss, R.B., Giermakowska, W., Hancock, R.B., Richieri, S.P., Theofan, G., Jensen, F.C., Salk, P., and Carlo, D.J.  The effect of dose and adjuvant on immunization with a whole-killed gp120-depleted HIV-1 antigen in a murine model for prophylactic vaccination.  Vaccine 16, 727-731, 1998.

 

Moss, R.B. and Salk, P.L.  CD8+ memory T cells require CD4+ help: Implication for therapeutic and preventive HIV vaccines.  AIDScience 3(15), 2003

 

Silvera, P., Savary, J.R., Livingston, V., White, J., Manson, K.H., Wyand, M.H., Salk, P.L., Moss, R.B., and Lewis, M.G.  Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques.  Vaccine 23, 827-839, 2004.

 

Salk, P.L.  Individual and Collective Consciousness as the Basis for Sustainable Development.  Proceedings of the Fifth International Conference on Sustainable Development, September 18‑19, 2017.